Plasma Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) as a Possible Biomarker for Severe COVID-19

Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces low density lipoprotein (LDL) uptake, leading to increased plasma levels of LDL. In addition, PCSK9 has been implicated in inflammation independently of the effects on cholesterol metabolism. The current analysis showed that our 156 patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Mester, Patricia, Amend, Pablo, Schmid, Stephan, Müller, Martina, Buechler, Christa, Pavel, Vlad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385877/
https://www.ncbi.nlm.nih.gov/pubmed/37515197
http://dx.doi.org/10.3390/v15071511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385877/
https://www.ncbi.nlm.nih.gov/pubmed/37515197
http://dx.doi.org/10.3390/v15071511

Ejemplares similares